Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple attack on pancreatic cancer: heat, chemo, and immunotherapy combined in new trial

NCT ID NCT06831136

Recruiting now Disease control Sponsor: The University of Texas Health Science Center, Houston Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II trial tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Participants first receive standard chemotherapy, then an endoscopic procedure that uses heat to destroy tumor tissue (EUS-RFA), followed by the immunotherapy drug pembrolizumab. The goal is to see if this combination can shrink tumors and improve outcomes. The study enrolls 24 adults with locally advanced or metastatic pancreatic ductal adenocarcinoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (immunotherapy) and endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA)
What this could lead to
If successful, this combination could shrink tumors and improve survival for people with advanced pancreatic cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (24 participants) testing a new combination. It may not work better than standard treatments, and side effects from the procedures and drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.